Semaglutide: Novo Nordisk opens a Phase 4 kidney and heart study in China
Novo Nordisk A/S has a Phase 4 study of once weekly subcutaneous semaglutide in adults in China with type 2 diabetes and chronic kidney disease listed as recruiting on ClinicalTrials.gov, with the record first posted on 28 October 2026.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk and sold as Ozempic (weekly injection, type 2 diabetes), Rybelsus (daily tablet, type 2 diabetes) and Wegovy (obesity, as a weekly injection and, since December 2025 in the US and July 2026 in the EU, as a daily pill).
Read the full guide →In 30 seconds
- A Phase 4 study of once weekly semaglutide injections is recruiting in China in adults who have type 2 diabetes and chronic kidney disease.
- The main outcome is the time to a first kidney or cardiovascular event, a composite that includes a persistent fall of at least 50% in eGFR compared with baseline, start of chronic kidney replacement therapy, kidney death and cardiovascular death.
- The design is a single treatment group with no masking, and the record lists estimated dates in December 2029 and January 2030.
Why it matters
Adults who live with both type 2 diabetes and chronic kidney disease carry risk in two organ systems at once, and this study puts both in the same protocol: its stated purpose is to find out what happens to kidney and heart health during treatment with semaglutide, given as an injection under the skin, and whether the medicine is safe in that population. The primary outcome is not a laboratory reading but the time to a first hard event, a composite that combines kidney failure events with cardiovascular death. The study is run in China by Novo Nordisk A/S, the sponsor listed in the registry entry, and the record states that it is not an FDA regulated drug study.
The details
- Who runs it: the sponsor is Novo Nordisk A/S, listed as an industry sponsor. Clinical Transparency (dept. 2834), Novo Nordisk A/S, is listed as study director.
- Status and dates: the overall status is recruiting, verified in October 2026. The record was first submitted on 21 October 2026 and first posted on 28 October 2026. It gives 12 October 2026 as an actual date, then 20 December 2029 and 24 January 2030 as estimated dates.
- Design: interventional, Phase 4, single group, no allocation, treatment as primary purpose, and no masking. Enrolment is given as 300 participants (estimated). There is one arm, labelled Semaglutide and marked experimental.
- Treatment: participants receive semaglutide by subcutaneous injection once weekly. The study is stated to last for about 60 to 172 weeks.
- Primary outcome: time to first occurrence of a composite endpoint that includes onset of a persistent reduction of at least 50% in eGFR compared with baseline, onset of a persistent eGFR below the low threshold defined in the record, initiation of chronic kidney replacement therapy, kidney death and cardiovascular death. Outcomes are measured from baseline (Week 0) up to Week 169.
- Secondary outcomes: change in eGFR by three creatinine or cystatin C based formulas, relative change in urine albumin to creatinine ratio (measured in percentage), time to all cause death, time to a first composite MACE event (non fatal myocardial infarction, non fatal stroke and cardiovascular death), change in glycated haemoglobin (HbA1c, in percentage points), number of serious adverse events and number of severe hypoglycaemic episodes.
- Who can join: adults aged 18 years or above at the time of signing the informed consent, diagnosed with type 2 diabetes, with HbA1c of 10% or less, and with kidney impairment defined by two combinations of eGFR range and urine albumin to creatinine ratio. Participants must be treated with the maximum labelled or tolerated dose of a renin angiotensin aldosterone system (RAAS) blocking agent, a class the record describes as including an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated. That treatment must have been stable for at least 4 weeks before the date of the laboratory assessments used to determine the inclusion criterion, and kept stable until screening. The number of participants whose inclusion eGFR is at or above the upper threshold defined in the record will be capped at 20% of enrolled participants.
- Who cannot join: people with congenital or hereditary kidney diseases, autoimmune kidney diseases or congenital urinary tract malformations; anyone who used a GLP-1 receptor agonist within 30 days before screening, which also covers dual agonists containing a GLP-1 receptor agonist component; myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 60 days before screening; current dialysis or dialysis within 90 days; uncontrolled and potentially unstable diabetic retinopathy or maculopathy; and combination use of an ACE inhibitor with an angiotensin II receptor blocker.
- Where: sites are listed across China, in Beijing, Shanghai and provinces including Anhui, Gansu, Guangdong, Hebei, Henan, Hubei, Inner Mongolia, Jiangsu, Jiangxi, Jilin, Liaoning, Qinghai, Shandong, Sichuan and Zhejiang. Beijing Anzhen Hospital, Capital Medical University, is listed as recruiting; the other listed sites, such as Fu Yang People's Hospital in Fuyang, are listed as not yet recruiting.
- Data sharing: individual participant data sharing is marked yes, according to the Novo Nordisk disclosure commitment on novonordisktrials.com.
What it does not change
This is a registry entry for a study that is still recruiting, not a result and not a regulatory decision. No outcome data are reported. The design is a single group with no allocation and no masking, so the record describes no comparator or placebo group against which the kidney and heart outcomes would be measured. The entry also states that there is no data monitoring committee and that the study is not an FDA regulated drug study, and most of the listed hospital sites are still marked not yet recruiting rather than open.
What's next
Recruitment continues at Beijing Anzhen Hospital, Capital Medical University, while the other listed sites remain marked not yet recruiting. The record states that the study will last for about 60 to 172 weeks, with outcomes assessed from baseline (Week 0) up to Week 169. Its later dates, 20 December 2029 and 24 January 2030, are both listed as estimated, so they can move. Novo Nordisk gives a contact telephone number and the address [email protected] in the entry, and states that individual participant data will be shared in line with its disclosure commitment.
What we don't know yet
The entry does not report how many participants have been enrolled so far, and it gives no results on the composite kidney and cardiovascular endpoint, on eGFR, on urine albumin to creatinine ratio, on HbA1c, on serious adverse events or on severe hypoglycaemic episodes. Because the listed design has a single group, the record does not describe any comparison with another treatment. It also does not state any interim analysis plan, and no data monitoring committee is listed. Everything above comes from the registry entry alone.
Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.
Source documents
This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.